3 months ago
54
3
Posted On: July 17th 2026, 12:00 pm
What will it take to unlock the next wave of investment in extracellular vesicle (EV) therapeutics?
Lonza recently brought together investors, biotech leaders and industry experts in Boston to discuss the future of the field. From scientific and clinical progress to manufacturing readiness and investment trends, the conversations explored the opportunities and challenges shaping the next phase of EV therapeutics.
Thank you to everyone who joined us and contributed to an open and insightful discussion.
Looking to advance your extracellular vesicle program? Connect with our team to explore how Lonza can support your development and manufacturing journey.
https://www.lonza.com/contact
Lonza recently brought together investors, biotech leaders and industry experts in Boston to discuss the future of the field. From scientific and clinical progress to manufacturing readiness and investment trends, the conversations explored the opportunities and challenges shaping the next phase of EV therapeutics.
Thank you to everyone who joined us and contributed to an open and insightful discussion.
Looking to advance your extracellular vesicle program? Connect with our team to explore how Lonza can support your development and manufacturing journey.
https://www.lonza.com/contact
Comments (3)
3 months agokonwalia47
You are disgusting, primitive, and cruel! You torture, abuse, and kill sentient beings solely for your profit. 🤬 STOP animal testing! 🛑 STOP animal cruelty! 🛑🐾⚖️🛑 No living being should have to suffer and die for science, cosmetics, or profit. ⚠️🐾⚠️
3 months agocarbonspherefullerene
Fascinating EV therapeutics discussion. Fullerene C60 offers complementary potential as a drug carrier — its nanoscale spherical geometry enables high drug-loading and surface functionalization. C60-EV hybrid systems could enhance targeted delivery. @CarbonSphere
More posts
